However, recent discoveries in breast cancer biology have identified therapeutic molecular targets within TNBC subtypes, including PARP inhibitors for the treatment of women with BRCA mutant breast cancers and immune checkpoint inhibitors for PD-L1-positive advanced disease (13–20). This evidence concerns the gene CD274 and breast cancer.